Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Advertisement
A phase I/II trial of LV20.19 showed a 100% ORR in patients with relapsed or refractory MCL.
Benefits of rituximab maintenance were observed despite the shift in first-line induction strategies over the years.
Brexucabtagene autoleucel in the standard-of-care setting for R/R MCL showed efficacy and toxicity “consistent” with ...
The FDA approved the first and only noncovalent BTK inhibitor for MCL.
Tycel Phillips, MD, discusses a study evaluating glofitamab in patients with relapsed/refractory mantle cell lymphoma.
A phase I/II study of zilovertamab and ibrutinib in R/R MCL showed the combination was well-tolerated.
Advertisement
Jonathon Cohen, MD, discusses how he came to focus on lymphoma, as well as current research, pressing questions, and more.
Orelabrutinib has been approved by the Health Sciences Authority of Singapore for the treatment of adults with MCL.
Experts discuss areas of progress and where more work is needed to establish a standard of care in mantle cell lymphoma.
The combination of acalabrutinib plus venetoclax and rituximab is well tolerated in treatment-naive MCL.
The triple chemotherapy-free combination of acalabrutinib, lenalidomide, and rituximab is well tolerated in MCL.
Jean Koff, MD, MSc, discusses research presented at ASH on the genomic characterization of mantle cell lymphoma.
David Bond, MD, discusses data on survival following MCL relapse from the LION Prospective Observational Registry.
Updated results from the phase I/II BRUIN study showed that pirtobrutinib continues to be well tolerated in R/R MCL.
Tycel Phillips, MD, of the City of Hope, talks about the TRIANGLE study and frontline therapy in mantle cell lymphoma.
Advances in treatment have led to improved outcomes in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
High-dose immunochemotherapy and AHSCT “failed to show superiority over” an ibrutinib-containing treatment without AHSCT. ...
Regulatory applications were filed for epcoritamab to treat R/R LBCL, DLBCL.
Jia Ruan, spoke on emerging treatment options for MCL in this interview from SOHO 2022.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726